Plant Summary
Plant Information
TCMBank_ID: | TCMBANKHE004220 |
YEM_ID: | YEM-273 |
ID: | TCMBANKHE004220/YEM-273 |
植物拉丁名: |
|
功能与主治: | To calm asthma, dispel wind, relieve pain./Cough and asthma, fright epilepsy, wind-cold-damp impediment, dysentery, prolapse of rectum, knocks and falls. |
药用植物名: | 曼陀罗子|洋金花 |
药名: | 洋金花 |
来源: | 云南民族药物志：第二卷 |
使用民族: | 傣族/傈僳族/彝族/壮族 |
TCM_ID_id: | 1315 |
植物对应的化合物
| 化合物ID | 化合物名 | 别名 | 分子式 | 分子质量 | Smiles |
|---|
| TCMBANKIN010981 | tropine | C8H15NO | 141.21 g/mol | CN1C2CCC1CC(C2)O | |
| TCMBANKIN017069 | tropinone | C8H13NO | 139.19 g/mol | CN1C2CCC1CC(=O)C2 | |
| TCMBANKIN027730 | hyoscyamine | Benzeneacetic acid, alpha-(hydroxymethyl)-, (3-endo)-8-methyl-8-azabicyclo(3.2.1)oct-3-yl ester, (alphaS)-, sulfate (2:1) (salt); Hyoscyamine sulfate anhydrous; Hyoscyamine sulfate (2:1) (salt); Hyoscyamine sulphate; C17H23NO3.H2O4S; Hyoscyamine Sulfate [USP]; Egazil; SCHEMBL34273; 1-alpha-H,5-alpha-H-Tropan-3-alpha-ol, (-)-tropate (ester), sulfate (2:1); Benzeneacetic acid, alpha-(hydroxymethyl)-, 8-methyl-8-azabicyclo(3.2.1)oct-3-yl ester, (3(S)-endo)-, sulfate (2:1) (salt); Hyoscyamine Sulfate (anhydrous); EINECS 210-644-6; Nulev; VJFQPODMEGSXHC-PGQIENJJSA-N; Levsin sulfate; LS-158068; Hyoscyamine sulfate (2:1); Hyoscyamine sulfate; TL8004024; CHEMBL1697729 | C17H23NO3 | 289.4 g/mol | CN1C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3 |
| TCMBANKIN030354 | Cyclofoetoside B | cyclofoetoside b | C47H80O18 | 933.13 | CC1C(C(C(C(O1)OCC2C(C(C(C(O2)OC3CC4(C5CCC6C(C(CCC67C5(C7)CCC4(C3C(C)CCC(C(C)(C)O)O)C)OC8C(C(C(CO8)O)O)O)(C)CO)C)O)O)O)O)O)O |
| TCMBANKIN040087 | 29-Norlanost-9(11)-enol | ||||
| TCMBANKIN043675 | 29-norlanosterol | C29H48O | 412.7 g/mol | CC1C2CCC3=C(C2(CCC1O)C)CCC4(C3(CCC4C(C)CCC=C(C)C)C)C | |
| TCMBANKIN043775 | cycloeucalenol | 4alpha,14-dimethyl-9beta,19-cyclo-5alpha-ergost-24(28)-en-3beta-ol; 9,19-Cycloergost-24(28)-en-3-ol, 4,14-dimethyl-, (3beta,4alpha,5alpha)-; 469-39-6; C02141; AKOS032948711; cycloleucalenol; CHEBI:16653; cycloeucalenol; 3beta,4alpha,5alpha-4,14-dimethyl-9,19-cycloergost-24(28)-en-3-ol | C30H50O | 427 | [C@]1([H])(O[H])[C@@]([H])(C([H])([H])[H])[C@@]2([H])[C@@]3([C@@]4(C3([H])[H])[C@]([H])([C@](C([H])([H])[H])(C([H])([H])C([H])([H])[C@@]5([C@]([H])(C([H])([H])[H])C([H])([H])C([H])([H])C(=C([H])[H])C( [H])(C([H])([H])[H])C([H])([H])[H])[H])[C@]5(C([H])([H])[H])C([H])([H])C4([H])[H])C([H])([H])C2([H])[H])C([H])([H])C1([H])[H] |
| TCMBANKIN045792 | Obtusifoliol | (3S,4S,5S,10S,13R,14R,17R)-4,10,13,14-tetramethyl-17-[(2R)-6-methyl-5-methylidene-heptan-2-yl]-1,2,3,4,5,6,7,11,12,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-ol; 16910-32-0; 4alpha,14alpha-Dimethyl-5alpha-ergosta-8,24(28)-dien-3beta-ol; obtusifoliol; (3S,4S,5S,10S,13R,14R,17R)-17-[(1R)-4-isopropyl-1-methyl-pent-4-enyl]-4,10,13,14-tetramethyl-1,2,3,4,5,6,7,11,12,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-ol; Ergosta-8,24(28)-dien-3-ol, 4,14-dimethyl-, (3beta,4alpha,5alpha)-; (3S,4S,5S,10S,13R,14R,17R)-17-[(1R)-1,5-dimethyl-4-methylene-hexyl]-4,10,13,14-tetramethyl-1,2,3,4,5,6,7,11,12,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-ol; 4alpha,14alpha-Dimethyl-24-methylene-5alpha-cholesta-8-en-3beta-ol; LMST01030101; 4alpha,14alpha-dimethyl-24-methylene-cholest-8-en-3beta-ol; (3S,4S,5S,10S,13R,14R,17R)-17-[(1R)-1,5-dimethyl-4-methylenehexyl]-4,10,13,14-tetramethyl-1,2,3,4,5,6,7,11,12,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-ol; (3S,4S,5S,10S,13R,14R,17R)-4,10,13,14-tetramethyl-17-[(2R)-6-methyl-5-methylideneheptan-2-yl]-1,2,3,4,5,6,7,11,12,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-ol; C01943; 22332-15-6 | 426.72 | ||
| TCMBANKIN048200 | hypaconitine | Hypaconitine; aconitine alkaloids | C33H45NO10 | 616 | C1([H])([H])[C@]([H])(OC([H])([H])[H])[C@]2([C@@]([H])([C@@]([H])([C@]3(OC(C([H])([H])[H])=O)[C@@]([H])([C@@]([H])(OC(=O)c4c([H])c([H])c([H])c([H])c4[H])[C@]([C@]([H])(OC([H])([H])[H])[C@]3([H])O[H])( O[H])C5([H])[H])[C@]25[H])[C@]6([H])OC([H])([H])[H])N(C([H])([H])[H])C7([H])[H])[C@@]6([H])[C@@]7(C([H])([H])OC([H])([H])[H])C1([H])[H] |
| TCMBANKIN057966 | CIR | C00327; EINECS 206-759-6; (2S)-2-amino-5-(carbamoylamino)pentanoic acid; (2S)-2-amino-5-ureidopentanoic acid; C7629_SIGMA; (2S)-2-amino-5-ureido-pentanoic acid; Citrulline, L-; alpha-Amino-delta-ureidovaleric acid; NSC 27425; (2S)-2-amino-5-(aminocarbonylamino)pentanoic acid; Ornithine, N5-(aminocarbonyl)-; N5-(Aminocarbonyl)ornithine; Ornithine, N5-carbamoyl-, L- (8CI); N(5)-(aminocarbonyl)-L-ornithine; SBB012374; N(delta)-Carbamylornithine; N(5)-carbamoyl-L-ornithine; (2S)-2-amino-5-ureido-valeric acid; (S)-2-Amino-5-ureidopentanoic acid; SMP1_000146; 2-Amino-5-ureidovaleric acid; NCGC00142602-01; L-2-Amino-5-ureidovaleric acid; delta-Ureidonorvaline; CHEBI:16349; citrulline; AB1007188; AC1LCUKE; d-citrullin; AK-58500; (R)-2-Amino-5-ureidopentanoic acid; MFCD00216469; KB-49607; D-Citruline; AX8031821; D-Ornithine,N5-(aminocarbonyl)-; W-204205; H-D-Orn(carbamoyl)-OH; (2R)-5-(aminocarbonylamino)-2-azanyl-pentanoic acid; DTXSID90348463; MolPort-003-928-964; 594C519; H-D-Cit-OH; D-Citrulline, >=99.0%; CTK4C0068; N(5)-carbamoyl-D-ornithine; AmbotzHAA1014; AJ-33795; AB0012765; ST24035348; ACM13594520; D-Citrulline; A807006; PubChem17499; TC-108738; J-300336; CHEBI:49007; SC-10122; C6H13N3O3; SCHEMBL437142; ANW-19993; AM82460; AS-12983; GTPL4683; ZINC2166829; FT-0659369; 13594-51-9; B-7191; D0V2DT; (2R)-2-amino-5-(carbamoylamino)pentanoic acid | C6H13N3O3 | 175.19 g/mol | C(CC(C(=O)O)N)CNC(=O)N |
| TCMBANKIN059715 | vitamin a | C20H30O | 286.5 g/mol | CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CCO)C)C | |
| TCMBANKIN060905 | Ricineic acid | C18H32O2 | 280.45 | CCCCCCC=CC=CCCCCCCCC(=O)O | |
| TCMBANKIN060958 | oleic acid;cis-oleic acid;oleinic acid | C18H34O2 | 282.46 | CCCCCCCCC=CCCCCCCCC(=O)O |
植物对应的疾病
| 疾病ID | 病名 | 疾病类型 | MeSH | 参考文献 |
|---|
植物对应的靶点
| 靶点ID | 基因名 | 基因别名 | 描述 | 染色体位置 | Map_Location | 基因类型 |
|---|
滇ICP备16009434号-1 |
Dai SX Lab